

Seraseq[®] Solid Tumor CNV FFPE and Mutation Mix

Comprehensive reference material for development, validation and clinical application of assays for copy number alterations in solid tumors

INTRODUCTION

Gene amplifications and deletions, collectively called copy number variations (CNVs), are common in cancer cells and contribute to uncontrolled cell growth, drug sensitivity and resistance. To support clinical labs performing next generation sequencing (NGS)-based tumor profiling of cancer patient samples and help assay developers develop and characterize the performance of their assays, SeraCare has developed a comprehensive solid tumor CNV reference material in formalin-fixed paraffin-embedded (FFPE) and mutation mix format.

This unique product includes a wide range of CNVs of clinically relevant genes associated with solid tumors. Amplifications of these target genes are quantitated by digital PCR (dPCR) and blended with the well-characterized GM24385 genomic background. Develop and validate your assay with confidence using the most comprehensive patient-like reference material on the market and ensure robust sensitivity using a single sample bearing a range of copy numbers to establish and challenge your assay's limit of detection (LOD).

FEATURES AND BENEFITS

- 12 clinically relevant CNVs associated with solid tumors
- Copy numbers quantified using sensitive dPCR assays and blended with the well-characterized GM24385 genomic background
- Validated by a targeted NGS panel
- Manufactured in GMP-compliant, ISO 13485-certified facilities
- The FFPE material is single reference material carrying gene amplifications at various levels
- Mutation mix format is available in +3, +6, and +12 copy formats

CNVs INCLUDED

Gene ID	Cancer Type
AKT2	Breast, Pancreatic, Ovarian, Lung, Colon, Bladder
BRAF	Breast, CRC, Melanoma, Prostate, Glioblastoma
EGFR	Glioblastoma, Lung, Breast, Esophageal, Colon
ERBB2	Breast, Esophageal, Lung, Colon, Bladder
FGFR3	Bladder, Breast, Pancreatic, Glioblastoma, Ovarian
KIT	Brain, Breast, GIST, Lung, Melanoma
KRAS	Lung, Breast, Esophageal, Ovarian, Pancreatic
MET	Lung, Glioblastoma, Colon, Esophageal, Gastric
MYC	Breast, Lung, Colon, Prostate, Breast, Ovarian
MYCN	Brain, Breast, Bladder, Uterine Corpus
NTRK1	Lung, Breast, Endometrial, Melanoma, Liver
PIK3CA	Breast, Lung, Ovarian, Anal, Head & Neck

HIGHLIGHTS

Highly multiplexed, containing 12 clinically relevant CNVs found in solid tumors

Quantitated with dPCR and validated with NGS; Ensures accurate and consistent detection of CNVs

High-quality manufactured reference material in full process format or purified DNA format

ORDERING INFORMATION

Material #	Product Description	Concentration	Fill Volume	Total Mass
0710-2865	Seraseq® FFPE Solid Tumor CNV RM	1 curl/vial	10 µm curl	>100 ng DNA
0710-2866	Seraseq® Solid Tumor CNV Mix, +3 copies	10 ng/µL	20 µL	200 ng DNA
0710-2867	Seraseq® Solid Tumor CNV Mix, +6 copies	10 ng/µL	20 µL	200 ng DNA
0710-2868	Seraseq® Solid Tumor CNV Mix, +12 copies	10 ng/µL	20 µL	200 ng DNA

To place an order, please contact us at +1.508.244.6400 and 800.676.1881 or email CDx-CustomerService@lgcgroup.com

For all solid tumor reference material, visit seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Solid-Tumors

ABOUT US

SeraCare offers a comprehensive portfolio of reference materials for oncology and reproductive health, designed and manufactured to meet the precision demanded by NGS assays. The portfolio includes high quality ground-truth RNA, ctDNA and genomic DNA-based reference materials that are NGS platform agnostic for tumor profiling, immuno-oncology, liquid biopsy, NIPT and germline cancer assay workflows. **For more information visit seracare.com**